What is Atomic AI?
Atomic AI operates at the intersection of artificial intelligence and life sciences, specializing in the discovery of RNA-targeted small molecules and RNA-based medicines. By leveraging a sophisticated research platform that combines advanced machine learning models with rigorous in-house wet-lab assays, the company is redefining the drug discovery pipeline. This dual-pronged methodology allows for the development of highly potent and selective therapeutics, positioning Atomic AI as a critical partner for pharmaceutical entities and research institutions seeking to navigate the complexities of modern drug development. The company's focus on AI-driven RNA innovation represents a significant shift in how the industry approaches previously undruggable targets.
How much funding has Atomic AI raised?
Atomic AI has raised a total of $35M across 1 funding round:
Series A
$35M
Series A (2023): $35M with participation from AME Cloud Ventures, The Factory HQ, Greylock Partners, Playground, and 8VC
Key Investors in Atomic AI
AME Cloud Ventures
A venture fund led by Jerry Yang that focuses on data-centric infrastructure and technology-heavy companies across various stages of the data stack.
Greylock Partners
A veteran venture capital firm with a long history of backing market-defining companies in enterprise software, AI, and infrastructure sectors.
8VC
A technology investment firm that manages significant committed capital, focusing on smart enterprise platforms within healthcare, Bio-IT, and logistics.
What's next for Atomic AI?
Following this major enterprise-level funding, Atomic AI is expected to scale its operational capacity and expand its clinical pipeline. The strategic infusion of capital will likely be directed toward enhancing its deep learning infrastructure and broadening its portfolio of RNA-based candidates. As the company matures, the focus will shift toward establishing high-value partnerships with global pharmaceutical leaders, further validating its platform's efficacy. By maintaining its commitment to data-centric drug discovery, Atomic AI is poised to become a cornerstone of the next generation of biotech innovation, potentially transforming the standard of care for various chronic and acute health conditions.
See full Atomic AI company page
